Global sales for the cervical and lumbar disc replacement devices were $23.4 million, according to a news release. Resources associated with the discs will be allocated to “more profitable growth opportunities.”
Orthofix will still fulfill requirements related to post-market surveillance activities and completion of an Investigational Device Exemption study in the U.S.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
